BRCA1 - Conductor of the Breast Stem Cell Orchestra: The Role of BRCA1 in Mammary Gland Development and Identification of Cell of Origin of BRCA1 Mutant Breast Cancer

Stem Cell Reviews and Reports

Volumn 8, Issue 3, 2012, Pages 982-993

  Buckley, Niamh E ^a   Mullan, Paul B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

BRCA1; Differentiation; Notch; p63; Stem cells

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN;

ANIMAL; BASAL CELL CARCINOMA; BREAST TUMOR; CANCER STEM CELL; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MAMMARY GLAND; MUTATION; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MUTATION; NEOPLASMS, BASAL CELL; NEOPLASTIC STEM CELLS;

EID: 84865540826     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-012-9354-y     Document Type: Review

References (78)

1. Miki, Y., Swensen, J., Shattuck-Eidens, D., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182), 66-71.
2. King, M. C., Marks, J. H., & Mandell, J. B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643-6.
3. Yang, Q., Sakurai, T., Mori, I., et al. (2001). Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer, 92, 54-60.
4. Turner, N., Tutt, A., & Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nature Reviews Cancer, 4(10), 814-9.
5. Anderson, S. F., Schlegel, B. P., Nakajima, T., Wolpin, E. S., & Parvin, J. D. (1998). BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nature Genetics, 19(3), 254-6.
6. Bochar, D. A., Wang, L., Beniya, H., et al. (2000). BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 102(2), 257-65.
7. Zhang, H., Somasundaram, K., Peng, Y., et al. (1998). BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene, 16(13), 1713-21.
8. Wang, Q., Zhang, H., Kajino, K., & Greene, M. I. (1998). BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene, 17(15), 1939-48.
9. Andrews, H. N., Mullan, P. B., McWilliams, S., et al. (2002). BRCA1 regulates the interferon gamma-mediated apoptotic response. Journal of Biological Chemistry, 277(29), 26225-32.
10. Mullan, P. B., Hosey, A. M., Buckley, N. E., et al. (2005). The 2, 5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis. Oncogene.
11. Shakya, R., Reid, L. J., Reczek, C. R., et al. (2011). BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science, 334(6055), 525-8.
12. Chang, S., Wang, R. H., Akagi, K., et al. (2011). Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nature Medicine, 17(11), 1521.
13. Foulkes, W. D. (2004). BRCA1 functions as a breast stem cell regulator. Journal of Medical Genetics, 41(1), 1-5.
14. Liu, S., Ginestier, C., Charafe-Jauffret, E., et al. (2008). BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of the National Academy of Sciences of the United States of America, 105(5), 1680-5.
15. Lim, E., Vaillant, F., Wu, D., et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 15(8), 907-13.
16. Proia, T. A., Keller, P. J., Gupta, P. B., et al. (2011). Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell, 8(2), 149-63.
17. Molyneux, G., Geyer, F. C., Magnay, F. A., et al. (2010). BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell, 7(3), 403-17.
18. Sorlie, T., Perou, C. M., Tibshirani, R., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 98(19), 10869-74.
19. Behbod, F., & Rosen, J. M. (2005). Will cancer stem cells provide new therapeutic targets? Carcinogenesis, 26(4), 703-11.
20. Polyak, K. (2007). Breast cancer: origins and evolution. The Journal of Clinical Investigation, 117(11), 3155-63.
21. Sorlie, T., Tibshirani, R., Parker, J., et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America, 100(14), 8418-23.
22. Liu, X., Holstege, H., van der Gulden, H., et al. (2007). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(29), 12111-6.
23. Poole, A. J., Li, Y., Kim, Y., Lin, S. C., Lee, W. H., & Lee, E. Y. (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science, 314(5804), 1467-70.
24. Dontu, G., Abdallah, W. M., Foley, J. M., et al. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes & Development, 17(10), 1253-70.
25. Prat, A., Parker, J. S., Karginova, O., et al. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research, 12(5), R68.
26. Herschkowitz, J. I., Simin, K., Weigman, V. J., et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology, 8(5), R76.
27. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. The New England Journal of Medicine, 346(21), 1616-22.
28. Narod, S. A., Brunet, J. S., Ghadirian, P., et al. (2000). Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet, 356(9245), 1876-81.
29. Huyton, T., Bates, P. A., Zhang, X., Sternberg, M. J., & Freemont, P. S. (2000). The BRCA1 C-terminal domain: structure and function. Mutation Research, 460(3-4), 319-32.
30. Yu, X., Chini, C. C., He, M., Mer, G., & Chen, J. (2003). The BRCT domain is a phospho-protein binding domain. Science, 302(5645), 639-42.
31. Monteiro, A. N., August, A., & Hanafusa, H. (1996). Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proceedings of the National Academy of Sciences of the United States of America, 93(24), 13595-9.
32. Chapman, M. S., & Verma, I. M. (1996). Transcriptional activation by BRCA1. Nature, 382(6593), 678-9.
33. Xu, X., Weaver, Z., Linke, S. P., et al. (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Molecular Cell, 3(3), 389-95.
34. Knudson, A. G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68(4), 820-3.
35. Fodde, R., & Smits, R. (2002). Cancer biology. A matter of dosage. Science, 298(5594), 761-3.
36. Bellacosa, A., Godwin, A. K., Peri, S., et al. (2010). Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prevention Research (Phila Pa), 3(1), 48-61.
37. Farmer, H., McCabe, N., Lord, C. J., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917-21.
38. Deng, C. X., & Brodie, S. G. (2000). Roles of BRCA1 and its interacting proteins. BioEssays, 22(8), 728-37.
39. Hohenstein, P., & Giles, R. H. (2003). BRCA1: a scaffold for p53 response? Trends in Genetics, 19(9), 489-94.
40. Martin, A.-M., Kanetsky, P., Amirimani, B., et al. (2003). Germline TP53 mutations in breast cancer families with multiple cancers: is TP53 a modifier if BRCA1? Journal of Medical Genetics, 40(4), e34.
41. Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., & Mak, T. W. (1997). Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nature Genetics, 16(3), 298-302.
42. Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., & Foulkes, W. D. (2001). TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Research, 61(10), 4092-7.
43. Hartman, A. R., & Ford, J. M. (2002). BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nature Genetics, 32(1), 180-4.
44. Smart, C. E., Clarke, C., Brooks, K. M., et al. (2008). Targeted disruption of Brca1 in restricted compartments of the mouse mammary epithelia. Breast Cancer Research and Treatment, 112(2), 237-41.
45. Cicalese, A., Bonizzi, G., Pasi, C. E., et al. (2009). The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell, 138(6), 1083-95.
46. Godar, S., Ince, T. A., Bell, G. W., et al. (2008). Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell, 134(1), 62-73.
47. Gusterson, B. A., Ross, D. T., Heath, V. J., & Stein, T. (2005). Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Research, 7(4), 143-8.
48. Chaffer, C. L., Brueckmann, I., Scheel, C., et al. (2011). Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America, 108(19), 7950-5.
49. Greaves, M. (2000). Cancer the evolutionary legacy. Oxford University Press.
50. Marquis, S. T., Rajan, J. V., Wynshaw-Boris, A., et al. (1995). The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genetics, 11(1), 17-26.
51. Rajan, J. V., Wang, M., Marquis, S. T., & Chodosh, L. A. (1996). Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 93(23), 13078-83.
52. Rajan, J. V., Marquis, S. T., Gardner, H. P., & Chodosh, L. A. (1997). Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Developmental Biology, 184(2), 385-401.
53. Bernard-Gallon, D. J., De Latour, M. P., Sylvain, V., et al. (2001). Brca1 and Brca2 protein expression patterns in different tissues of murine origin. International Journal of Oncology, 18(2), 271-80.
54. Xu, X., Wagner, K. U., Larson, D., et al. (1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, 22(1), 37-43.
55. Kubista, M., Rosner, M., Kubista, E., Bernaschek, G., & Hengstschlager, M. (2002). Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene, 21(31), 4747-56.
56. Furuta, S., Jiang, X., Gu, B., Cheng, E., Chen, P. L., & Lee, W. H. (2005). Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proceedings of the National Academy of Sciencesof the United States of America.
57. Hosey, A. M., Gorski, J. J., Murray, M. M., et al. (2007). Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. Journal of the National Cancer Institute, 99(22), 1683-94.
58. Gorski, J. J., James, C. R., Quinn, J. E., et al. (2009). BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Research and Treatment.
59. Kennedy, R. D., Gorski, J. J., Quinn, J. E., et al. (2005). BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Research, 65(22), 10265-72.
60. Buckley, N. E., Conlon, S. J., Jirstrom, K., et al. (2011). The {Delta}Np63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. Cancer Research, 71(5), 1933-44.
61. Yalcin-Ozuysal, O., Fiche, M., Guitierrez, M., Wagner, K. U., Raffoul, W., & Brisken, C. (2010). Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. Cell Death and Differentiation, 17(10), 1600-12.
62. Buono, K. D., Robinson, G. W., Martin, C., et al. (2006). The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Developmental Biology, 293(2), 565-80.
63. Raouf, A., Zhao, Y., To, K., et al. (2008). Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell, 3(1), 109-18.
64. Tkocz, D., Crawford, N. T., Buckley, N. E., et al. (2011). BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene.
65. Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D., & Werb, Z. (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 127(5), 1041-55.
66. Carroll, D. K., Carroll, J. S., Leong, C. O., et al. (2006). p63 regulates an adhesion programme and cell survival in epithelial cells. Nature Cell Biology, 8(6), 551-61.
67. Taddei, I., Deugnier, M. A., Faraldo, M. M., et al. (2008). Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nature Cell Biology, 10(6), 716-22.
68. LaBarge, M. A., Nelson, C. M., Villadsen, R., et al. (2009). Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. Integrative Biology (Cambridge), 1(1), 70-9.
69. Welcsh, P. L., Lee, M. K., Gonzalez-Hernandez, R. M., et al. (2002). BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7560-5.
70. Visvader, J. E. (2011). Cells of origin in cancer. Nature, 469(7330), 314-22.
71. Fialkow, P. J., Denman, A. M., Jacobson, R. J., & Lowenthal, M. N. (1978). Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J Clin Invest, 62(4), 815-23.
72. Jamieson, C. H., Ailles, L. E., Dylla, S. J., et al. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. The New England Journal of Medicine, 351(7), 657-67.
73. Greaves, M. (2010). Cancer stem cells: back to Darwin? Seminars in Cancer Biology, 20(2), 65-70.
74. Keller, P. J., Arendt, L. M., Skibinski, A., et al. (2011). Defining the cellular precursors to human breast cancer. Proceedings of the National Academy of Sciencesof the United States of America.
75. Ince, T. A., Richardson, A. L., Bell, G. W., et al. (2007). Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell, 12(2), 160-70.
76. Hennessy, B. T., Gonzalez-Angulo, A. M., Stemke-Hale, K., et al. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research, 69(10), 4116-24.
77. Prat, A., & Perou, C. M. (2009). Mammary development meets cancer genomics. Nature Medicine, 15(8), 842-4.
78. Lehmann, B. D., Bauer, J. A., Chen, X., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation, 121(7), 2750-67.